AstraZeneca Reports P-III (POSEIDON) Trial Results of Imfinzi (durvalumab) for Metastatic Non-Small Cell Lung Cancer
Shots:
- The P-III (POSEIDON) trial evaluates Imfinzi + Imfinzi & tremelimumab & CT vs CT alone in 1013 patients with m-NSCLC
- The results showed OS benefits (25%). In the post-hoc, exploratory analyses, OS improvement in patients with STK11, KEAP1 & KRAS-mutated NSCLC with a 38% reduction in risk of death & also shown in patients with ≤1% PD-L1 tumor cell expression & 32% in non-sq. histology with m-OS of 17.2mos. vs 13.1mos., patients were alive (31.4% vs 17.3%) @3yr. The results were consistent with prior P-III (POSEIDON) trial
- In ITT/ STK11 mutation/KEAP1/KRAS mutation, m-OS (14.0 vs 11.7mos./15.0 vs 10.7mos./13.7 vs 8.7mos./25.7 vs 10.4mos.); OS rate @3yr. (25.0% vs 13.6%/25.8% vs 4.5%/30.0% vs 0.0%/40.0% vs 15.8%), respectively
Ref: AstraZeneca | Image: AstraZeneca
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
